CTLA-4 Protein- Cytotoxic T-lymphocyte protein 4 recombinant protein

Reference:
Product nameCTLA-4 Protein- Cytotoxic T-lymphocyte protein 4 recombinant protein
Uniprot IDP16410
Uniprot linkhttp://www.uniprot.org/uniprot/P16410
Origin speciesHomo sapiens (Human)
Expression systemEukaryotic expression
SequenceMACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDGSHHHHHH
Molecular weight18.51kDa
Protein delivered with Tag?Yes
Purity estimated95%
Buffer50 mM Tris-HCl, pH 8.0, 150 mM NaCl
FormLyophilized
Delivery conditionDry Ice
Delivery lead time in business days5-7
Storage condition4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB
Fragment TypePartial
Aliases /SynonymsCTLA4, Cynw2, CD152, CELIAC3, CTLA4, GSE, IDDM12, Celiac Disease 3, Cytotoxic T-lymphocyte protein 4
ReferencePX-P4018
NoteFor research use only

Description of CTLA-4 Protein- Cytotoxic T-lymphocyte protein 4 recombinant protein

General Information On CTLA-4 protein

CTLA-4 protein (cytotoxic T-lymphocyte-associated protein 4) also known as Cluster of Differentiation 152 (CD152) is a protein receptor that acts as an immune checkpoint. CD152 protein is expressed in regulatory T cells. CTLA-4 protein is upregulated following T cell activation.
CTLA-4 protein is homologues to CD28 protein although they have opposite functions. CTLA-4 protein transmits inhibitory signals to T cells hence acting as ‘off’ switch whereas CD28 is a T-cell co-stimulatory protein. They both bind to CD80 and CD86 on antigen presenting cells. Furthermore, CD152 bind to CD80 and CD86 with a greater affinity than CD28 and surpasses CD28 activity on the ligands. Research data (Stamper et al. 2001) showed that CTLA-4 and CD80 a periodic arrangement in which bivalent CTLA-4 homodimers bridge bivalent CD80 homodimers. It is believed that this oligomerization provides the structural basis for forming unusually stable signaling complexes at the T-cell surface.
The structure of CTLA-4 protein consist in an extracellular V domain, a transmembrane domain and a cytoplasmic tail. The membrane-bound isoform functions as a homodimer interconnected by a sulfide bond whereas the soluble isoform functions as a monomer. CTLA-4 protein has an intracellular domain which is believed to have no intrinsic catalytic activity. This intracellular domain, similar to that of CD28, contains one YVKM motif that binds PI3K, PP2A, SHP-2 and one proline rich motif that binds to SH3 containing proteins. It is believed that CTLA-4 inhibits T cell activity through SHP-2 and PP2A dephosphorylation of TCR-proximal signaling proteins (CD3 and LAT).

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “CTLA-4 Protein- Cytotoxic T-lymphocyte protein 4 recombinant protein”

Your email address will not be published. Required fields are marked *

Related products

Rituximab Biosimilar – Anti-MS4A1 mAb – Research Grade
Biosimilar

Rituximab Biosimilar – Anti-MS4A1 mAb – Research Grade

PX-TA1010 300€
Abatacept Biosimilar – Anti-CTLA-4 extracellular domain linked to IgG1 Fc mAb – Research Grade
Biosimilar

Abatacept Biosimilar – Anti-CTLA-4 extracellular domain linked to IgG1 Fc mAb – Research Grade

PX-TA1020 400€
Ipilimumab Biosimilar – Anti-CTLA-4 mAb – Research Grade
Biosimilar

Ipilimumab Biosimilar – Anti-CTLA-4 mAb – Research Grade

PX-TA1021 300€
Navicixizumab Biosimilar – Anti-DLL4 mAb – Research Grade
Biosimilar

Navicixizumab Biosimilar – Anti-DLL4 mAb – Research Grade

PX-TA1026 400€
Romilkimab Biosimilar – Anti-IL13, IL4 mAb – Research Grade
Biosimilar

Romilkimab Biosimilar – Anti-IL13, IL4 mAb – Research Grade

PX-TA1027 400€
Ruplizumab Biosimilar – Anti-CD40LG mAb – Research Grade
Biosimilar

Ruplizumab Biosimilar – Anti-CD40LG mAb – Research Grade

PX-TA1036 400€
Eculizumab Biosimilar – Anti-C5 mAb – Research Grade
Biosimilar

Eculizumab Biosimilar – Anti-C5 mAb – Research Grade

PX-TA1039 300€
Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade
Biosimilar

Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade

PX-TA1040 300€
Matuzumab Biosimilar – Anti-EGFR mAb – Research Grade
Biosimilar

Matuzumab Biosimilar – Anti-EGFR mAb – Research Grade

PX-TA1041 300€
Epratuzumab Biosimilar – Anti-CD22 mAb – Research Grade
Biosimilar

Epratuzumab Biosimilar – Anti-CD22 mAb – Research Grade

PX-TA1042 400€
Cantuzumab Biosimilar – Anti-CA242 mAb – Research Grade
Biosimilar

Cantuzumab Biosimilar – Anti-CA242 mAb – Research Grade

PX-TA1045 400€
Labetuzumab Biosimilar – Anti-CEACAM5 mAb – Research Grade
Biosimilar

Labetuzumab Biosimilar – Anti-CEACAM5 mAb – Research Grade

PX-TA1048 400€
Motavizumab Biosimilar – Anti-RSV mAb – Research Grade
Biosimilar

Motavizumab Biosimilar – Anti-RSV mAb – Research Grade

PX-TA1052 400€
Natalizumab Biosimilar – Anti-ITGA4, CD49d mAb – Research Grade
Biosimilar

Natalizumab Biosimilar – Anti-ITGA4, CD49d mAb – Research Grade

PX-TA1053 300€
Interleukin-4 receptor subunit alpha(IL4R)
Receptor

Interleukin-4 receptor subunit alpha(IL4R)

PX-P4860 210€
CCL4L1, N-GST, recombinant protein
Ligand

CCL4L1, N-GST, recombinant protein

PX-P5546 385€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products